BCL10

Across TCGA pan-cancer cohorts, BCL10 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated BCL10 data layer compared with 27 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher BCL10 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated BCL10 expression acts as an unfavorable survival marker, although some lineages such as UCEC and LUAD show a favorable association.

CCRCC, UCEC, and LUAD are the cancer types where BCL10 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	OS	Quartile	All	0.774	1.000	.004	38	view →
UCEC	DFS	Quartile	III,IV	1.000	0.271	.006	24	view →
LUAD	OS	Median	III,IV	0.799	0.434	.007	8	view →
PDAC	DFS	Median	III,IV	0.544	0.795	.024	7	view →
LSCC	OS	Tertile	All	0.941	0.839	.040	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

BCL10–CCRCC (OS)

Open the CCRCC breakdown →